Poster Abstract: Based on the clinical and commercial success of SARS-CoV-2 mRNA vaccines, interest in using lipid nanoparticle-formulated mRNA (LNP-mRNA) as a next generation, rapidly deployable vaccine platform has accelerated in the form of preclinical research and clinical trials. To democratize access to a reliable supply of high purity mRNA and LNPmRNA, Vernal Biosciences designs, manufactures, and formulates LNP-mRNA as an on-demand service for all stages of research and development. In order to validate our platform technologies, we manufactured two mRNA COVID-19 vaccine mimics called VRN-S-1 and VRN-S-2. In this study, we report that both mRNAs are of high integrity and both LNP-mRNA formulations are sized below 100nm, exceed 90% encapsulation efficiency, and feature low polydispersity indices. Using a prime-boost dosing regimen, we intramuscularly injected VRN-S-1 and VRN-S-2 into BALB/c mice and collected serum 2 weeks after the boost injection for sera titering. Both VRN-S-1 and VRN-S-2 potently induced high levels of total IgG and SARSCoV-2 S protein-specific IgG. These preclinical results are comparable to the previously reported sera titers results for two of the commercially available COVID-19 LNP-mRNA vaccines. These results confirm that Vernal Biosciences can manufacture high-purity LNP-mRNA that ultimately meets levels the of biological activity of high impact LNP-mRNA products.
